# Phase 2 clinical trial

> The mid-stage of drug testing in patients, designed to show early evidence that a drug works, refine the dose and further assess safety.

Source: https://www.quantisnow.com/glossary/phase-2-trial
Topic: Glossary / Biotech and FDA
Also known as: Phase 2 trial, Phase II trial, Phase 2b, proof-of-concept trial
Last updated: 2026-10-27

A Phase 2 clinical trial is the stage of drug development that tests an investigational drug in patients with the target condition to gather early evidence of efficacy, identify the best dose and continue evaluating safety. It bridges the safety focus of [Phase 1](https://www.quantisnow.com/glossary/phase-1-trial) and the large confirmatory trials of [Phase 3](https://www.quantisnow.com/glossary/phase-3-trial).

## How it works

Phase 2 studies usually enroll from several dozen to a few hundred patients. They are often split into:

- **Phase 2a:** smaller proof-of-concept studies asking whether the drug has any effect.
- **Phase 2b:** larger, often randomized and placebo-controlled studies comparing doses to choose the one for Phase 3.

Endpoints may be clinical outcomes or biomarkers. Many Phase 2 trials are randomized and blinded, but single-arm designs are common in oncology, where response rate is compared against historical benchmarks. Strong Phase 2 data can support [breakthrough therapy designation](https://www.quantisnow.com/glossary/breakthrough-therapy) and, in some cases, [accelerated approval](https://www.quantisnow.com/glossary/accelerated-approval).

At the end of Phase 2, sponsors typically meet with the FDA to agree on the design of pivotal trials.

## Why it matters for traders

Phase 2 is where many drugs fail, and it is often the most important readout for an early-stage biotech's valuation because it is the first real test of efficacy. Traders scrutinize:

- Whether the trial hit its [primary endpoint](https://www.quantisnow.com/glossary/primary-endpoint) with statistical significance.
- Effect size versus placebo and versus competing drugs.
- Dose response, which supports that the effect is real.
- Safety signals that could limit the commercial profile.

## Example

Northwind Therapeutics (NWTX) runs a randomized Phase 2b in 240 patients across three doses and placebo (60 per arm). The high dose cuts disease flares by 50% versus placebo, the mid dose by 30%, and the low dose by 10%. The clean dose response supports moving the high dose into Phase 3.

## FAQ

### What is the difference between Phase 2a and 2b?

Phase 2a is a smaller early test of whether the drug works. Phase 2b is usually larger and randomized, designed to pick the dose for Phase 3.

### Can a drug be approved after Phase 2?

Sometimes, for serious diseases with unmet need, under accelerated approval or when a large randomized Phase 2 is compelling. Most drugs still need Phase 3.

## Related terms

- [Phase 1 clinical trial](https://www.quantisnow.com/glossary/phase-1-trial.md): The first stage of human testing for a new drug, focused on safety, tolerability, dosing and how the body processes it, usually in a small group.
- [Phase 3 clinical trial](https://www.quantisnow.com/glossary/phase-3-trial.md): The large, late-stage trial that tests whether a drug works and is safe in a broad patient population, usually forming the basis for an FDA application.
- [Topline data](https://www.quantisnow.com/glossary/topline-data.md): The first high-level results from a clinical trial, usually covering the primary endpoint and key safety findings, released before the full dataset.
- [Primary endpoint](https://www.quantisnow.com/glossary/primary-endpoint.md): The main outcome a clinical trial is designed and statistically powered to measure, used to judge whether the drug worked.
- [Breakthrough therapy designation](https://www.quantisnow.com/glossary/breakthrough-therapy.md): An FDA designation that speeds development of a drug for a serious condition when early clinical data show substantial improvement over existing therapy.
- [Accelerated approval](https://www.quantisnow.com/glossary/accelerated-approval.md): An FDA pathway approving drugs for serious conditions based on a surrogate endpoint, with confirmatory trials required to verify clinical benefit.

## On Quantisnow

- [Clinical trial phases explained](https://www.quantisnow.com/guides/clinical-trial-phases)
- [Live feed: FDA Approvals](https://www.quantisnow.com/news/fda)
- [FDA approval process](https://www.quantisnow.com/guides/fda-approval-process)
- [Latest clinical trial results](https://www.quantisnow.com/top/clinical-trial-results)